# Phase 3 colorectal cancer trials recruiting: 62 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 62 trials in phase 3 for colorectal cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 colorectal cancer trials: 62 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/colorectal-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 62
- Recruiting or not yet: 62
- Read on: November 19, 2026

## Trials

The 25 newest of 62, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 3, 2026 | NCT07913360 | GFH375 Plus Cetuximab vs Investigator's Choice of Treatment in KRAS G12D-Mutant Refractory Metastatic Colorectal Cancer | Genfleet Therapeutics (Shanghai) Inc. | Phase 3 | Not yet recruiting | Colorectal Cancer | 368 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07913360) |
| October 21, 2026 | NCT07885384 | Fruquintinib Combined With Capecitabine as Adjuvant Extended Therapy After R0 Resection and Perioperative Chemotherapy in Patients With... | West China Hospital | Phase 3 | Not yet recruiting | Colorectal Cancer | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07885384) |
| August 20, 2026 | NCT07775287 | Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent... | Genmab | Phase 3 | Recruiting | Colorectal Cancer | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07775287) |
| August 6, 2026 | NCT07750158 | Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular... | Exelixis | Phase 3 | Recruiting | Colorectal Cancer | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07750158) |
| July 28, 2026 | NCT07730489 | A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior... | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Colorectal Cancer | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07730489) |
| July 27, 2026 | NCT07729605 | FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC | Sun Yat-sen University | Phase 3 | Not yet recruiting | Colorectal Cancer Metastatic, Microsatellite Stable (MSS) Colorectal Cancer (CRC) | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07729605) |
| July 23, 2026 | NCT07722494 | IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer | Innovent Biologics (Suzhou) Co. Ltd. | Phase 3 | Recruiting | Colorectal Cancer | 550 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07722494) |
| May 27, 2026 | NCT07609901 | Preventive Dendritic Cell Vaccination for Lynch Syndrome Carriers | Radboud University Medical Center | Phase 3 | Not yet recruiting | Lynch Syndrome | 372 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07609901) |
| May 19, 2026 | NCT07595276 | Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF... | Taizhou Mabtech Pharmaceutical Co.,Ltd | Phase 3 | Recruiting | Colorectal Cancer | 608 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07595276) |
| April 24, 2026 | NCT07549412 | A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With... | EMD Serono Research & Development Institute, Inc. | Phase 3 | Recruiting | Metastatic Colorectal Cancer | 1,020 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07549412) |
| April 13, 2026 | NCT07525206 | A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV... | AbbVie | Phase 3 | Recruiting | Colorectal Cancer | 990 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07525206) |
| February 5, 2026 | NCT07389265 | Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer | University of Campania Luigi Vanvitelli | Phase 3 | Recruiting | Metastatic Colorectal Cancer (mCRC) | 480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07389265) |
| January 23, 2026 | NCT07362836 | Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS) | Fudan University | Phase 3 | Not yet recruiting | Colorectal Cancer | 224 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07362836) |
| January 22, 2026 | NCT07361003 | A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer | Jiangsu Simcere Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Refractory Metastatic Colorectal Cancer | 464 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07361003) |
| December 30, 2025 | NCT07309289 | NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer | Shanghai Zhongshan Hospital | Phase 3 | Recruiting | Metastatic Colorectal Cancer (CRC) | 144 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07309289) |
| December 16, 2025 | NCT07284849 | A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line... | Incyte Corporation | Phase 3 | Recruiting | CRC (Colorectal Cancer) | 700 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07284849) |
| December 16, 2025 | NCT07284394 | Liver-directed Chemotherapy After Surgery of Liver Metastases of Colorectal Cancer in Patients With High Risk of Recurrence of Their Disease | UNICANCER | Phase 3 | Not yet recruiting | Colorectal Adenocarcinoma Metastatic in the Liver, Colorectal Cancer | 272 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07284394) |
| December 9, 2025 | NCT07271355 | Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With... | City of Hope Medical Center | Phase 3 | Recruiting | Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum, Stage... | 129 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07271355) |
| November 14, 2025 | NCT07228832 | Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer | Summit Therapeutics | Phase 3 | Recruiting | Metastatic Colorectal Cancer (CRC) | 900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07228832) |
| October 30, 2025 | NCT07222800 | Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With... | Pfizer | Phase 3 | Recruiting | Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Digestive System... | 800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07222800) |
| August 21, 2025 | NCT07134205 | The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer | Shanghai JMT-Bio Inc. | Phase 3 | Not yet recruiting | Metastatic Colorectal Cancer (mCRC) | 252 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07134205) |
| June 17, 2025 | NCT07025239 | QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic... | Qilu Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Metastatic Colorectal Cancer | 430 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07025239) |
| June 13, 2025 | NCT07018869 | Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer... | SWOG Cancer Research Network | Phase 3 | Recruiting | Colorectal Cancer Stage II, Colorectal Cancer Stage III | 1,057 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07018869) |
| June 4, 2025 | NCT07004413 | Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients | Charite University, Berlin, Germany | Phase 3 | Not yet recruiting | Colorectal Cancer Metastatic | 267 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07004413) |
| May 28, 2025 | NCT06992648 | Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer | Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 3 | Recruiting | Colorectal Cancer Metastatic, Colorectal Cancer Recurrent | 302 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06992648) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Sun Yat-sen University | 5 |
| Fudan University | 4 |
| Sixth Affiliated Hospital, Sun Yat-sen University | 3 |
| [Janssen Research & Development, LLC](https://specstream.ai/data/clinical-trials/company/janssen-research-and-development-llc) | 2 |
| [Qilu Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/qilu-pharmaceutical-co-ltd) | 1 |
| [Genmab](https://specstream.ai/data/clinical-trials/company/genmab) | 1 |
| UNICANCER | 1 |
| Shanghai Zhongshan Hospital | 1 |
| National Cancer Center Hospital East | 1 |
| [Incyte Corporation](https://specstream.ai/data/clinical-trials/company/incyte-corporation) | 1 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 1 |
| [Shanghai JMT-Bio Inc.](https://specstream.ai/data/clinical-trials/company/shanghai-jmt-bio-inc) | 1 |
| The Netherlands Cancer Institute | 1 |
| City Clinical Oncology Hospital No 1 | 1 |
| City of Hope Medical Center | 1 |
| Genfleet Therapeutics (Shanghai) Inc. | 1 |
| Taizhou Mabtech Pharmaceutical Co.,Ltd | 1 |
| Zhejiang University | 1 |
| [Exelixis](https://specstream.ai/data/clinical-trials/company/exelixis) | 1 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 1 |
| [Innovent Biologics (Suzhou) Co. Ltd.](https://specstream.ai/data/clinical-trials/company/innovent-biologics-suzhou-co-ltd) | 1 |
| West China Hospital | 1 |
| Surgimab | 1 |
| Charite University, Berlin, Germany | 1 |
| [Sichuan Baili Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd) | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 30 |
| United States | 15 |
| Germany | 11 |
| Italy | 11 |
| Netherlands | 10 |
| Spain | 10 |
| Japan | 9 |
| Belgium | 9 |
| France | 9 |
| Puerto Rico | 8 |
| Poland | 7 |
| Canada | 6 |
| South Korea | 6 |
| United Kingdom | 6 |
| Taiwan | 6 |
| Australia | 5 |
| Brazil | 5 |
| Argentina | 4 |
| Denmark | 4 |
| Hungary | 4 |
| Sweden | 4 |
| Austria | 3 |
| Israel | 3 |
| Hong Kong | 3 |
| India | 3 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Meat wholesalers in the United States](https://specstream.ai/data/businesses/meat-wholesalers/united-states)
- [Sports medicine clinics in the United States](https://specstream.ai/data/businesses/sports-medicine-clinics/united-states)
- [Beer bars in the United States](https://specstream.ai/data/businesses/beer-bars/united-states)
- [Forestry services in the United States](https://specstream.ai/data/businesses/forestry-services/united-states)
- [Outpatient care facilities in the United States](https://specstream.ai/data/businesses/outpatient-care-facilities/united-states)
- [Uniform stores in the United States](https://specstream.ai/data/businesses/uniform-stores/united-states)
